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Background: Direct-acting antivirals (DAA) have revolutionized the therapy of chronic 
hepatitis C (CHC) and have replaced previous PEG-interferon/ribavirin (PEG-IFN/RBV) 
treatment. Patients with CHC and advanced liver disease are at increased risk for hepatocel-
lular carcinoma (HCC). However, the effects of DAA-based CHC treatment on subsequent 
HCC incidence remain poorly understood.
Patients and Methods: This retrospective single-institution cohort study included 243 
consecutive patients after PEG-IFN/RBV and 263 patients after DAA treatment. 
Multivariable cause-specific Cox proportional hazards models were used to compare time 
to HCC between treatment types, censoring patients who died or had an orthotopic liver 
transplantation (OLT) at the time of the competing event. Age, gender, BMI, viral load, 
cirrhosis, fibrosis stage, diabetes, virus genotype and previous PEG-IFN/RBV (before DAA) 
were used as covariates. In addition, we performed a propensity score-matched analysis.
Results: Nineteen HCC cases were observed after DAA therapy compared to 18 cases after 
PEG-IFN/RBV treatment. Patients were followed for a median of 4.1 years (IQR: 3.5–4.7) 
for DAA and 9.3 years (IQR: 6.6–12.4) for the PEG-IFN/RBV group. In an unadjusted Cox 
model, a hazard ratio (HR) of 6.40 (CI: 2.20–18.61, p=0.006) for HCC following DAA vs 
PEG-IFN/RBV was estimated. In multivariable Cox proportional hazard models, age and 
liver cirrhosis were identified as further HCC risk factors but the HR estimates for DAA vs 
PEG-IFN/RBV still indicate a considerably increased hazard associated with DAA treatment 
(HR between 7.23 and 11.52, p≤0.001, depending on covariates). A HR of 6.62 (CI: 2.01– 
21.84, p=0.002) for DAA vs PEG-IFN/RBV was estimated in the propensity score-matched 
analysis. The secondary outcomes death and OLT did not differ between treatment groups.
Conclusion: In a cohort study from a tertiary care hospital rates of HCC after the start of 
DAA treatment were higher compared to PEG-IFN/RBV treatment. Our data reinforce the 
recommendation that surveillance should be continued after successful CHC treatment.
Keywords: hepatocellular carcinoma, chronic hepatitis C, direct-acting antivirals, PEG- 
interferon and ribavirin, viral load, liver transplantation, sustained virological response
Introduction
Hepatocellular carcinoma is the fifth and ninth most common cancer in men and 
women, respectively.1 Chronic infection with hepatitis C virus (HCV) is one of the 
leading risk factors for HCC. The annual risk of HCC is as high as 3% in patients 
with cirrhosis and untreated HCV.2 In the past decades, the standard of care for 
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chronic HCV was pegylated interferon and Ribavirin 
(PEG-IFN/RBV). These drug regimens achieved a consid-
erable proportion of sustained virological response (SVR) 
of about 44–63% and large studies described a reduced 
risk for HCC following successful HCV treatment with 
PEG-IFN/RBV.3–5 However, side effects and toxicities 
forced a substantial percentage of patients to stop treat-
ment early. The recent implementation of highly effective 
and well-tolerated direct-acting antivirals (DAA) has led 
to very high SVR of more than 90% in most HCV patient 
populations. Within the next decade, most patients with 
known HCV in Western countries are expected to start 
DAA treatment and achieve SVR.6–8
Recently, DAA have come under scrutiny for a possi-
ble increase in HCC incidence after DAA treatment and 
current data on HCC recurrence or development following 
DAA-induced SVR are still conflicting. Initial studies 
reported higher rates of HCC occurrence than expected 
in patient cohorts treated with DAA,9–11 which were con-
troversially discussed.12 These findings were not con-
firmed in all studies.13–15 In larger studies, the risk for 
HCC upon DAA treatment was higher upon DAA treat-
ment compared to controls with PEG-INF/RBV treatment 
or no treatment; however, this increased risk was elimi-
nated or reversed after correction for confounders.16–20 A 
recent meta-analysis indicated a reduced or similar risk of 
HCC upon DAA treatment21 and overall, DAA-induced 
SVR was protective against the development of HCC.22–24 
However, considering the broad use of DAA among HCV 
patients and the deleterious effect of HCC more data in all 
possible settings are clearly needed.
With this manuscript, we present a large retrospective 
single-center cohort study at the University Hospital 
Zürich, Switzerland examining HCC incidence after 
DAA treatment in comparison to previous PEG-IFN/ 
RBV data from the same institution.
Patients and Methods
Patients with PEG-IFN/RBV treatment between 16th of 
January 1998 and 6th of April 2013 and DAA treatment 
starting between 1st of November 2013 and 31st of May 
2016 were included. Pre-existing HCC orthotopic liver 
transplantation (OLT) before the start of therapy and 
unknown HCC status before or after treatment were exclu-
sion criteria. PEG-IFN/RBV treatment in a significant 
fraction of HCV patients is a clinical fact in many hepa-
tology units worldwide and this considerable fraction of 
patient cannot be ignored in our real-life analysis. 
Therefore, in a pragmatic approach, patients who received 
sequential therapies with PEG-IFN/RBV followed by 
DAA were evaluated in the DAA cohort, but potential 
confounding by previous PEG-IFN/RBV treatment was 
accounted for in the statistical analysis (see below).
All time intervals were calculated with the first day of 
PEG-IFN or DAA treatment as time origin. In one patient 
who had 2 rounds of DAA, we combined the 2 treatment 
rounds, with the start of the first round as time origin. 
Diagnosis of HCC followed established guidelines by the 
European Association for the Study of the Liver (EASL).25
Our study was approved by the Ethics Committee of 
Zurich county (KEK Zurich, BASEC 2019-00072). The 
need for individual patient consent to retrospective data 
review was waived by the Ethics Committee because 
patient consent to anonymized data evaluation already 
existed within the Swiss Hepatitis cohort study. This 
Swiss Hepatitis cohort study has been approved by KEK 
Zurich (EK-695). The study was performed in accordance 
with the declaration of Helsinki. Patient data were anon-
ymized and patient data confidentiality was observed as 
required by general consent regulations.
Measures
Patients were considered negative for HCC if dedicated 
imaging (either abdominal ultrasound or contrast- 
enhanced MRI) at most 6 months prior to treatment was 
without evidence for HCC. For all other patients, HCC 
state was considered unknown. Patients within the HCV 
treatment group received annual ultrasonography of the 
liver while patients with known cirrhosis received biann-
ual surveillance by ultrasound. Suspicious lesions were 
followed by MRI.
Sustained virological response (SVR) was defined as 
negative HCV PCR 12 weeks and 24 weeks after end of 
treatment for DAA and PEG-IFN/RBV treated patients, 
respectively. Since PEG-IFN/RBV treatment is frequently 
accompanied by severe side effects resulting in a difficult 
decision-making process, whether treatment would need to 
be stopped, we aimed to understand severity of liver dis-
ease and urgency of treatment before start of treatment. 
For this reason, biopsies were performed close to the start 
of PEG-IFN/RBV treatment (median 0.47 years, IQR 
0.13–2 before start) but at a longer time period before 
DAA (3.5 years, IQR 1.3–7.2). Liver fibrosis was assessed 
by liver biopsy following METAVIR criteria (F1-F4)26 or 
estimated from transient elastography data. For measure-
ment of transient elastography, the Echosens FibroScan 
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502 Touch machine was used with the following published 
cut-off values >12.5: F4; >9.5: F3, >7.0: F2, all others F0 
or F1.27 The Echosens FibroScan 502 machine was only 
introduced in 2012, and fibroscan measures were not 
available before that point in time. For these reasons, 
fibroscan measures are more prevalent in the DAA 
group. Transient elastography measurements were 
acquired at a median of 0.2 years (IQR 0.1–0.4) before 
DAA and 0.5 years (0.2–1) before PEG-IFN/RBV treat-
ment. Cirrhosis was defined either by biopsy, by a transi-
ent elastography (Fibroscan) value >12.5 kPa or according 
to clinical, endoscopic and/or ultrasound criteria (ie severe 
liver disease with clear radiographic or endoscopic signs 
of portal hypertension).
AST to platelet ratio (APRI)28 and FIB-429 were cal-
culated using measurements at the start of HCV therapy. 
The MELD score was calculated as previously described;-
30 values <6 and values for individuals without liver cir-
rhosis were fixed at 6. Since platelet counts are a part of 
APRI and FIB-4, and bilirubin is contained in the MELD 
score, no independent correction for platelets and bilirubin 
as covariates was performed. Further alpha-fetoprotein 
(AFP) values were missing in 90 patients after DAA and 
27 after PEG-IFN/RIB treatment, precluding correction 
for AFP.
Statistical Analysis
Patient baseline characteristics were summarized per treat-
ment group (PEG-IFN/RBV, DAA) for the eligible 
patients included in the data analysis. Frequencies and 
percentages are shown for categorical variables. Medians 
and interquartile ranges are shown for continuous 
variables.
To estimate the hazard ratio of DAA vs PEG-IFN/RBV 
for the primary outcome (time to) HCC we used cause- 
specific Cox proportional hazards models. Death and OLT 
were treated as competing risks by right-censoring patients 
at the competing event. In two cases, discovery of HCC 
and death or OLT were recorded on the same day. Under 
the assumption that HCC was present before the other 
events, we counted both cases as HCC events. Patients 
without event were right-censored at the last follow-up 
visit. The minimal model (a) only includes treatment 
(DAA vs PEG-IFN/RBV) as explanatory variable, our 
factor of main interest. To address the problem of con-
founding, other risk factors for HCC were added as cov-
ariates to the model. However, due to the limited number 
of HCC events, we did not include all relevant risk factors 
in a single model to avoid overfitting. Applying the ten 
events per variable rule of thumb,31 we limited the number 
of predictors to four per model. We fitted several alterna-
tive adjusted models to assess the robustness of the treat-
ment effect estimate in this observational cohort study and 
to investigate which risk factors for HCC may be most 
relevant. Each model includes treatment and age (a well- 
known risk factor), and either (b) sex and previous treat-
ment with PEG-IFN/RBV, (c) cirrhosis and fibrosis grade 
(d) BMI and diabetes, (e) viral load (in 1ʹ000ʹ000 interna-
tional units/mL), or (f) virus genotype as additional cov-
ariates. Moreover, we assessed the interaction between age 
and treatment. The secondary outcomes time to death and 
time to OLT were analyzed by cause-specific Cox propor-
tional hazards models with age and treatment as explana-
tory variables.
Times to HCC, death and liver transplantation were 
visualized using cumulative incidence curves.
Moreover, we performed the following sensitivity ana-
lyses to estimate the hazard ratio of DAA vs PEG-IFN/ 
RBV for the primary outcome (time to) HCC, which are 
presented in the Supplementary Materials: (1) A multi-
variate Cox model including FIB-4 as continuous variable 
instead of fibrosis degree, due to the many missing values 
in fibrosis degree, (2) models a—c described above but 
excluding DAA patients previously treated with PEG-IFN/ 
RBV and (3) a propensity score matched analysis (detailed 
description in the Supplementary Materials). All computa-
tions were performed using R version 4.0.2.32
Results
We identified 345 patients with DAA treatment and 276 
patients with PEG-IFN/RBV treatment. Of the patients 
with DAA treatment, 105 had received DAA after PEG- 
IFN/RBV (Figure 1). After exclusion of patients due to 
preexisting HCC, unknown HCC state after the start of 
therapy or previous OLT, 263 patients with DAA treatment 
(thereof 76 who received DAA after PEG-IFN/RBV) and 
243 patients with PEG-IFN/RBV treatment were included 
for further analysis (Figure 1).
Patients treated with DAA had a significantly higher 
body mass index (BMI) than PEG-IFN/RBV patients. 
Furthermore, genotypes 1 and 4 were more frequent in 
the DAA cohort (most likely due to higher rates of suc-
cessful previous PEG-IFN/RBV treatment of patients with 
genotypes 2 and 3 in our cohort). Liver cirrhosis assessed 
either by liver biopsy, transient elastography or ultrasound 
with appropriate clinical context was more prevalent in the 
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DAA cohort (both CHILD class A and B). The APRI and 
MELD scores were similar in both groups; however, 
DAA-treated patients had significantly higher FIB-4 scores 
(Table 1). HCC treatment resulted in SVR in 248/263, 
94.3% of DAA treated patients and 133/243, 54.7% of 
PEG-IFN/RBV patients.
After start of treatment, patients were followed for a 
median of 4.1 years (IQR: 3.5–4.7) for the DAA group and 
9.3 years (IQR: 6.6–12.4) for the PEG-IFN/RBV group. 
Nineteen patients were diagnosed with HCC with DAA 
compared to 18 patients with PEG-IFN/RBV. However, 
follow-up upon DAA treatment is significantly shorter in 
Figure 1 Flowchart of patient recruitment. 
Notes: All patients had known HCC status before treatment. The initial number of patients was 621 (PEG-IFN/RBV + DAA). Following the exclusion criteria, as shown in 
Figure 1, there were 506 eligible and thus analyzed patients. Patient characteristics are shown in Table 1. 
Abbreviations: DAA, directly acting antivirals; HCC, hepatocellular carcinoma; PEG-IFN/RBV, pegylated interferon/ribavirin; OLT, orthotopic liver transplantation.
Table 1 Overview of the Baseline Characteristics for Both Treatment Groups for Eligible Patients
PEG-IFN/RBV DAA p-value
n 243 263
Sex m 152 (62.6) 161 (61.2) 0.828
f 91 (37.4) 102 (38.8)
Diabetes No 212 (89.1) 233 (88.6) 0.977
Yes 26 (10.9) 30 (11.4)
Cirrhosis No 184 (75.7) 170 (64.6) 0.009
Yes 59 (24.3) 93 (35.4)
Genotype 1 129 (53.1) 175 (66.5) 0.002
2 29 (11.9) 18 (6.8)
3 63 (25.9) 41 (15.6)
4 22 (9.1) 29 (11.0)
Previous PEG-IFN/RBV No 243 (100) 187 (70.7) < 0.001
Yes 0 (0) 76 (29.3)
Fibrosis Grade 1 33 (17.6) 31 (15.3) 0.220
2 48 (25.7) 52 (25.6)
3 67 (35.8) 60 (29.6)
4 39 (20.9) 60 (29.6)
Child-Pugh-Score A 55 (22.6) 83 (31.6) 0.018
B 4 (1.6) 10 (3.8)
MELD 6 177 (74.7) 190 (72.2) 0.729
Abbreviations: DAA, direct-acting antivirals; PEG-IFN/RBV, pegylated interferon/ribavirin; MELD, Model for End-Stage Liver Disease.
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our cohort, and no data beyond about 2000 days (5.5 
years) after end of treatment are available. In a simple 
cause-specific Cox-proportional hazards model with treat-
ment (DAA or PEG-IFN/RBV) as the only explanatory 
variable, the hazard ratio for DAA vs PEG-IFN/RBV 
regarding HCC was 6.4 (95% CI: from 2.20 to 18.61, 
p=0.0006), Table 2A.
Treatment specific cumulative incidence curves of 
DAA and PEG-INF/RBV patients for HCC, death and 
OLT are shown in Figure 2.
Age is an important risk factor for HCC and was 
significant in all covariate-adjusted cause-specific Cox- 
proportional hazards models (HR 1.01–1.06 per additional 
year of age, Supplementary Table S1A–D). Neither epide-
miological parameters such as sex or previous treatment 
with PEG-IFN/RBV (Table 2B) nor metabolic parameters 
such as BMI and diabetes mellitus (Table 2C) were sig-
nificantly associated with time to HCC. However, there is 
evidence that cirrhosis is associated with shorter time to 
HCC (HR 3.82, 95% CI: from 1.25 to 11.67). The degree 
of fibrosis (F3-4 vs F0-2) was not significantly associated 
with time to HCC (Table 2C).
All our models suggest that patients under DAA treat-
ment developed HCC significantly faster than patients 
under PEG-IFN/RBV (p≤0.01 for all models). The size 
of the effect varied slightly (HR 6.4–7.2). The HR of the 
unadjusted model is in the same range as the adjusted 
HRs, suggesting a consistent association of DAA treat-
ment with a higher hazard of HCC compared to PEG- 
IFN/RBV even after adjustment for different potential 
confounders.
The relatively large HR estimate for DAA vs PEG- 
IFN/RBV described above was also robust in several sen-
sitivity analyses presented in Supplementary Tables S1, S2 
and S3. When FIB-4 was used instead of fibrosis degree, 
the HR was 3.63 (95% CI: from 1.18 to 11.21) 
(Supplementary Materials Table S1). Further, adjustment 
for HCV genotype (1 vs 2–4) or viral load resulted in a HR 
for DAA vs PEG-IFN/RBV of 7.49 (95% CI: from 2.53 to 
22.21) and 11.52 (95% CI: from 2.91 to 45.61), respec-
tively. When DAA patients previously treated with PEG- 
IFN/RBV were excluded, the HR for the models analogue 
to Table 2A–C were 6.16–6.97 (Supplementary 
Table S2A–C). The full and detailed description of the 
propensity score-matched analysis is sectioned in the 
Supplementary Materials (detailed description of methods 
in used as a complementary approach to adjust for con-
founders led to similar results). A detailed description of 
the methods used for propensity score matching is given 
together with Supplementary Figure S1. The unadjusted 
model on the propensity score matched data set estimated 
an HR of 6.62 (95% CI 2.01–21.84, p=0.002) and models 
adjusted for age and genotype (which were not so well 
balanced after matching, Supplementary Figure S2) or for 
age, cirrhosis and fibrosis degree event estimated slightly 
larger HR (Supplementary Table S3A–C).
When looking at an interaction of age and treatment, 
we found evidence for an increase in the HR for DAA 
Table 2 Hazard Ratio Estimates (with 95% Confidence Intervals) 
for Treatment (DAA vs PEG-IFN/RBV) and Important Covariates 
from Cause-Specific Cox Proportional Hazards Models on Time 
to HCC. The Hazard Ratio for Treatment is Once Estimated 
without Adjustment for Other Known or Potential Risk Factors 
for HCC (A), and with Adjustment for Different Sets of Other 










Age (years) 1.05 1.02–1.09 0.001
Female sex 0.65 0.32–1.31 0.23
Previous PEG-IFN/RBV 1.15 0.45–2.94 0.77







Age (years) 1.04 1.01–1.08 0.021
Liver cirrhosis 3.82 1.25–11.67 0.019
Fibrosis Grade 3–4 vs 0–2 1.04 0.31–3.47 0.95
Treatment DAA 7.23 2.14–24.38 0.003
Notes: Reading example: Overall in our cohort, patients treated with DAA devel-
oped HCC with an approximately 6-fold hazard compared to patients treated with 
PEG-IFN/RBV control (HR 6.40, A). Adjusted for the most important other risk 
factors age, liver cirrhosis and fibrosis degree, the HR changes to 7.23 (C). 
Moreover, patients with cirrhosis had an almost four-fold hazard to develop HCC 
than those without cirrhosis. Fibrosis degree 3–4 did not increase the hazard much 
compared to fibrosis degree 0–2, but it must be noted that this estimate is itself 
adjusted for cirrhosis. This means, we estimate the HR for Fibrosis degree 3–4 vs 
0–2, given a patient either has cirrhosis, or not. Model (A) and (B) included the total 
number of 506 patients with 37 HCC events. Due to missing data on fibrosis grade, 
model (C) included only 390 patients with 33 HCC events. Age in years. 
Abbreviations: DAA, direct-acting antivirals; PEG-IFN/RBV, pegylated interferon/ 
ribavirin; CI, confidence interval.
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vs PEG-IFN/RBV with patient age, suggesting a stron-
ger DAA-associated HCC risk in older patients 
(Supplementary Table S1D).
Investigating the associations of age and 
treatment with the secondary outcomes time to death 
(Table 3A) and time to OLT (Table 3B) in a 
Figure 2 Treatment specific cumulative incidence curves for (A) HCC, (B) death and (C) OLT. Numbers at risk are given at the bottom. 
Abbreviations: DAA, direct-acting antivirals; PEG-IFN/RBV, pegylated interferon/ribavirin; OLT, orthotopic liver transplantation.
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cause-specific Cox model, we could not detect any 
significant effects.
Discussion
We performed a retrospective analysis of HCC incidence 
in a cohort of HCV-infected patients who received DAA or 
PEG-IFN/RBV treatment. We would like to emphasize the 
following key observations: i) In our cohort we observed a 
high number of HCC cases within the first 2000 days after 
DAA treatment. Time to HCC was significantly shorter 
compared to the PEG-IFN/RBV treatment group, even 
after covariate adjustment. ii) As expected, additional 
risk factors for HCC after HCV treatment include older 
age and liver cirrhosis, pointing to subpopulations with 
highly increased HCC risks. iii) While HCC risk seems 
highest within the first 2 years following DAA treatment 
not a single case of HCC was observed within the first 2 
years following PEG-IFN/RBV and the incidence rises 
after well more than 10 years after treatment. iv) The 
DAA group showed higher rates of liver cirrhosis and 
higher FIB-4 scores compared to the PEG-IFN/RBV, indi-
cating more severe disease. This might be due to the ear-
lier availability of DAA treatment in younger HCV 
patients with more severe HCV. However, the association 
of DAA treatment with time to HCC remained robust even 
after controlling for these confounders as covariates, or 
after or in a propensity score matched analysis where these 
confounders were included in the propensity score model.
Within the last years, the relationship between DAA 
therapy and new onset of HCC has been intensely exam-
ined and discussed. A number of initial studies suggested 
an increased risk;9–11 nonetheless, a number of large and 
well-designed studies demonstrated an increased nominal 
risk upon DAA treatment which was eliminated or 
reversed after controlling for confounders.16–20 Studies 
comparing DAA-treated patients with a historical control 
of PEG-IFN/RBV patients, similar to our study, also 
showed similar HCC rates with both treatments.15,18,33,34 
The largest study cohort consisted of 62,000 patients trea-
ted for CHC;17 after controlling for a large set of confoun-
ders, eradication of HCV with DAAs was associated with 
a considerable reduction of HCC risk. Compared to PEG- 
INF treatment, the authors observed an unadjusted HR for 
HCC of 2.81 (CI: 2.44–3.22) associated with DAA treat-
ment; however, after adjustment for confounders, the 
adjusted hazard ratio was reduced to 1.12 (0.95–1.32). In 
this study, all HCC cases developing within the first 6 
months after completion of DAA were excluded to limit 
study results to truly de novo HCC and the time window 
immediately following HCV clearance has not been 
addressed. However, this difference is unlikely to explain 
the discrepant results completely.
HCC rates after CHC treatment were shown to be 
independent from the specific DAA used, arguing against 
direct toxic effects of different DAAs.35 A meta-analysis 
estimated an incidence rate of new HCC of 2.96/100 
person years after DAA and 1.14/100-person years after 
PEG-IFN/RBV. However, also in this meta-analysis, after 
controlling for confounders, no significant difference in 
HCC risk between DAA and PEG-IFN/RBV remained.20 
Why controlling for confounders or a propensity score- 
matched analysis did not eliminate the DAA-associated 
HCC risk in our study remains unclear.
Age remains a strong risk factor for HCC in our study 
and in most previous analyses.15,17,18,33,34 In our analyses, 
we found a statistical interaction of age and treatment, in 
line with a higher DAA-associated HCC risk in older 
patients. Somewhat similar, in a previous study liver fibro-
sis was a strong risk factor for HCC in younger individuals 
while older patients developed HCC independently from 
fibrosis state.36 However, even when interactions of treat-
ment and/or fibrosis with age were considered, a DAA- 
associated risk for HCC remained in our cohort and the 
age distribution in our cohort is similar as in previous 
studies.
SVR rates upon DAA treatment were high in our 
cohort (94.3%), as expected. Previous studies demon-
strated a protective effect of SVR regarding new onset of 
HCC.17,22–24 However, following CHC treatment, SVR 
should be considered an intermediate variable, a parameter 
Table 3 Hazard Ratio Estimates from a Cause-Specific Cox 
Proportional Hazards Model on Time to Death (A) and 
Orthotopic Liver Transplantation (OLT) (B)
A
Hazard Ratio 95% CI p-value
Age (years) 1.00 0.96–1.04 0.93
Treatment DAA 1.98 0.61–6.48 0.26
B
Hazard Ratio 95% CI p-value
Age (years) 1.04 0.99–1.09 0.15
Treatment DAA 0.13 0.02–1.00 0.05
Notes: The total of 506 patients was included in both models. Model (A) included 
18 deaths, model (B) 12 OLT. Age in years. 
Abbreviations: DAA, direct-acting antivirals; CI, confidence interval.
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affected by the treatment, which may or may not lie on the 
causal path to the outcome. To avoid the introduction of 
bias, correction for intermediate variables is usually 
discouraged37 and we did not use SVR as an explanatory 
variable in our analyses.
Recent reviews and guidelines conclude that the risk of 
de novo HCC after therapy is reduced.25,38 However, it 
should be noted that a considerable HCC risk remained in 
all studies even after successful treatment of HCV. In a 
recent meta-analysis, the incidence rate of new HCC was 
3.3% (95% CI 1.2–9%) per year after DAA.39 Some 
studies noted a much higher HCC risk within the first 
year after treatment than thereafter.13,23
In our study, a high incidence of HCC after the start of 
therapy was noted. One possible explanation of these 
results could be a change in the growth of pre-existing 
subclinical, undetectable HCC upon DAA treatment. In 
this scenario, DAA treatment would trigger a boost in 
HCC within a short time window after HCV clearance 
despite long-term benefits of DAA. Such an acceleration 
of HCC growth may be due to changes in immune-sur-
veillance of HCC upon DAA clearance. Our results are in 
line with a recent report, demonstrating a high HCC risk 
following DAA treatment, especially in individuals with 
uncharacterized liver nodules.40 Further, an HCC specific 
tumor response, which was reduced upon DAA-induced 
HCV clearance was recently described.41 This T cell- 
dependent immune response was much weaker in HCV 
patients who subsequently developed HCC.41 In addition 
to changes in immune surveillance, other mechanisms 
like cellular behavior after eradication of HCV for 
increased HCC growths upon DAA therapy have also 
been identified in early test models and will be elucidated 
in future clinical models.38 If confirmed, it would be 
important to identify patients susceptible to rapid HCC 
growth. However, it should be noted that our study only 
provides indirect evidence and neither proves accelera-
tion of HCC growth nor changes in HCC immune sur-
veillance directly.
Our study has several strengths and limitations. We 
included a relatively large population of HCV-infected 
individuals and a PEG-IFN/RBV treated control cohort 
from our center, allowing for direct assessment of con-
founders. In addition, median follow-up time in our study 
is 4.1 years for DAA and 9.3 years for PEG-IFN/RBV. The 
most important limitation of our study is the retrospective 
study design and for some measures our data are not 
complete. In addition, since the time of infection with 
HCV is not known for most of the patients, we cannot 
correct for duration of disease in our multivariable analysis 
or for propensity score matching. Finally, our study inevi-
tably compares newer DAA data with older PEG-IFN/ 
RBV data.
For practical purposes, our study serves as a reminder 
of the remaining HCC risk even after HCV clearance. A 
patient with long-term CHC is an HCC high-risk patient 
also after therapy and thus we recommend HCC surveil-
lance in 6-month intervals for patients with cirrhosis and a 
maximum of 12 months for patients without cirrhosis 
should be strictly followed.
In summary, we describe a cohort of patients with 
chronic hepatitis C infection and treatment with DAA or 
PEG-IFN/RBV. In our cohort, a higher hazard for devel-
oping HCC was noted upon DAA treatment compared to 
PEG-IFN/RBV also after adjustment for confounders. 
Therefore, a high degree of suspicion for HCC is justified 
after the start of DAA therapy, especially in high-risk 
patients.
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